Management of abnormal uterine bleeding among hormonal subdermal implant users. Abnormal uterine bleeding Hormonal subdermal implant Conjugated equine estrogen Nonsteroidal anti-inflammatory drugs
Conditions
Interventions
Conjugated equine estrogens one capsule (0.625 mg/capsule) two times a
day for 5 days,Mefenamic acid two capsules (250 mg/ capsule) three times a day for 5
days
Experimental Drug,Experimental Drug
Conjugated equine estrogens ,Mefenamic acid
Sponsors
Khonkean hospital
Eligibility
Sex/Gender
Female
Age
15 Years to 50 Years
Inclusion criteria
Inclusion criteria: Non pregnant women age 15 years old or older with using Single rod 68 mg Etonogestrel inserted 3 to 36 months before enrollment for contraception dysmenorrhea and complaints abnormal uterine bleeding
Exclusion criteria
Exclusion criteria: 1. Gynecological or medical diseases is cause abnormal uterine bleeding 2. Contraindicationorallergytoestrogenornonsteroidalanti-inflammatorydrugs 3. Chronicuseofnonsteroidalanti-inflammatorydrugs(morethantwotabletsthreetimesa week)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The duration of abnormal uterine bleeding among hormonal subdermal implant users was stopped after using of Conjugated equine estrogen and Nonsteroidal anti- inflammatory drug Duration of bleeding was stopped Calculated by Two independence means | — |
Secondary
| Measure | Time frame |
|---|---|
| The percentage of women who stopped bleeding within 7 days after initiation of treatment Less than 7 Days to stop bleeding Percentage (%),the adverse effects of using Conjugated equine estrogen and Nonsteroidal anti- inflammatory drug When person have adverse effect Number of person | — |
Countries
Thailand
Contacts
Public ContactSalinee Polyota
Khon kean hospital
Outcome results
None listed